Tango Therapeutics (NASDAQ:TNGX – Free Report) had its price objective lowered by Barclays from $18.00 to $13.00 in a report published on Friday morning, Benzinga reports. The brokerage currently has an overweight rating on the stock. A number of other equities analysts have also recently commented on TNGX. Cantor Fitzgerald initiated coverage on shares of […]